Amphastar Pharmaceuticals, Inc. - 8-K Filing
Amphastar Pharmaceuticals reported Q1 2026 net revenues of $171.2 million (flat YoY), GAAP net income of $6.4 million ($0.14 EPS), and adjusted non-GAAP net income of $19.5 million ($0.42 EPS). Revenue declines were driven by lower average selling prices for BAQSIMI® (-$8M) and Glucagon (-$11.7M), partially offset by growth in other products including albuterol, iron sucrose, and teriparatide. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $AMPH